Join/Renew Membership for SCC

Become part of our community of dedicated professional and student members today — join now.

New Members

Download Member ApplicationNew SCC Members may register online or download a writable .PDF membership application and email to Colleen Daddino at All major credit cards are accepted. Please use this form to type all your information. Once complete, please save the file on your computer, then email Colleen Daddino at or fax it to (212) 668-1504. The Society prefers typed applications over handwritten for ease of processing. Incomplete applications will delay the processing of your membership.

Existing SCC Members

Current SCC Members can easily renew online. Please take the time to renew your membership today to avoid reinstatement fees and any interruption in benefits.

Safety/Efficacy of New Topical Silicone Formulation with Selective Growth Factors for Treating Striae Distensae

Journal of Cosmetic Science | Volume 71 No 2
Authored by Robin Kikuchi, Andrea R. Waldman, Erik M. Wolfswinkel, Vadim Pletzer, Brandon D. Kalasho, and Christopher I. Zoumalan


Striae distensae (SD) are linear dermal scars that arise from progressive stretching or tearing of the dermal layer. This study tests the safety and efficacy of a topical formulation of silicone-based scar cream containing selective synthetic recombinant human growth factors, hyaluronic acid, and vitamin C to improve overall appearance and texture of SD. Twenty-two subjects with SD alba were recruited and randomized to apply the topical formula to half of their SD laterally twice a day for 1 month. Patient surveys were obtained at 1 month for overall appearance, texture, and tolerability. Three-dimensional imaging was obtained at baseline and at 1 month and submitted to independent evaluators for grading on overall appearance. Subjects reported improved texture and appearance in 86.4% of SD. Subjects reported 100% of untreated SD to have no change in overall appearance or texture. 90.9% of subjects reported no tolerability issues. 9.1% of the treated group reported mild issues such as slight itching or redness the first day of application, which subsided in 2 days for all patients. Independent evaluators indicated improvement in 72.7% of SD in comparison to improvement in 36.3% of untreated SD. This study demonstrates that the investigated topical formulation is safe and effective to use for SD.


For the Full Article, click here